Get the Stockscreener App
790.26
12.12%
-86.74
Regencell Bioscience Holdings Ltd Stock (RGC) Forecast
The Regencell Bioscience Holdings Ltd (RGC) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $20.02, representing a -97.47% decrease from the current price of $790.26. The highest analyst price target is $23.51, and the lowest is $16.53.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RGC Price Target
Average 15.94
(-97.98% Downside)
Is Regencell Bioscience Holdings Ltd (RGC) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 70.84 | Sell |
| STOCH(9,6) | 84.06 | Sell |
| STOCHRSI(14) | 32.10 | Neutral |
| MACD(12,26) | 160.70 | Buy |
| ADX(14) | 56.44 | Buy |
| William %R | -26.54 | Neutral |
| CCI(14) | 113.44 | Buy |
Buy: 3
Sell: 2
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
561.77
Buy
|
598.86
Buy
|
| MA20 |
427.49
Buy
|
461.83
Buy
|
| MA50 |
192.31
Buy
|
270.92
Buy
|
| MA100 |
99.57
Buy
|
161.33
Buy
|
| MA200 |
52.84
Buy
|
90.92
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, RGC could be considered a Strong Buy, with 17 technical analysis indicators signaling 13 Buy signals, 2 signaling Sell signals and 2 Neutral signals. This might be a good time to open fresh positions on RGC, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 70.84 indicates that RGC is overbought. This suggests that RGC price has experienced a significant increase over a specified lookback period, potentially leading to a correction.
- STOCH (Stochastic Oscillator): The STOCH value of 84.06 indicates that RGC is oversold. This means that RGC price is at or near the highest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 32.1 indicates that RGC is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 56.44 suggests an extremely strong trend in the market. Such high values are relatively rare and indicate a very robust directional movement.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 113.44 indicates that RGC is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term RGC price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Regencell Bioscience Holdings Ltd financial reports and earnings history, Regencell Bioscience Holdings Ltd (RGC) stock could reach $7.9008 by 2030, $25.44 by 2040 and $4.2668 by 2050. See the projected annual prices until 2050 of the Regencell Bioscience Holdings Ltd stock below:
- Regencell Bioscience Holdings Ltd (RGC) is expected to reach an average price of $6.4115 in 2035, with a high prediction of $4.8315 and a low estimate of $3.9437. This indicates an $-99.19% rise from the last recorded price of $790.26.
- Regencell Bioscience Holdings Ltd (RGC) stock is projected to chart a bullish course in 2040, with an average price target of $26.67, representing an $-96.63% surge from its current level. The forecast ranges from a conservative $27.04 to a sky-high $25.44.
- Our analysts predict Regencell Bioscience Holdings Ltd (RGC) to jump -88.67% by 2045, soaring from $82.32 to an average price of $89.54, potentially reaching $80.34. While $82.32 is the low estimate, the potential upside is significant.
- Regencell Bioscience Holdings Ltd (RGC) stock is expected to climb by 2050, reaching an average of $4.8904, a $-99.38% jump from its current level. However, a wide range of estimates exists, with high and low targets of $4.2668 and $4.8904, respectively, highlighting the market's uncertainty.
Regencell Bioscience Holdings Ltd Stock (RGC) Year by Year Forecast
Regencell Bioscience Holdings Ltd Stock (RGC) Price Forecast for 2025
Regencell Bioscience Holdings Ltd Stock (RGC) is expected to reach an average price of $21.54 in 2025, with a high prediction of $35.94 and a low estimate of $7.1521. This indicates an -97.27% fall from the last recorded price of $790.26.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| July, 2025 | $17.52 | $16.53 | $23.51 | -97.78% |
| August, 2025 | $19.57 | $13.34 | $22.92 | -97.52% |
| September, 2025 | $21.22 | $17.33 | $24.50 | -97.31% |
| October, 2025 | $19.49 | $18.29 | $22.54 | -97.53% |
| November, 2025 | $19.98 | $19.94 | $24.50 | -97.47% |
| December, 2025 | $18.66 | $15.44 | $22.18 | -97.64% |
Regencell Bioscience Holdings Ltd Stock (RGC) Price Forecast for 2026
The predicted value for Regencell Bioscience Holdings Ltd (RGC) in 2026 is set at an average of $14.83. Estimates vary from a peak of $24.66 to a trough of $4.9966, indicating an -98.12% surge from the present price of $790.26.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $20.15 | $18.12 | $22.89 | -97.45% |
| February, 2026 | $19.32 | $17.97 | $24.54 | -97.55% |
| March, 2026 | $15.61 | $15.61 | $19.38 | -98.02% |
| April, 2026 | $17.56 | $15.80 | $24.66 | -97.78% |
| May, 2026 | $11.77 | $11.09 | $16.95 | -98.51% |
| June, 2026 | $11.96 | $7.2221 | $13.34 | -98.49% |
| July, 2026 | $13.64 | $6.3883 | $14.04 | -98.27% |
| August, 2026 | $12.44 | $10.95 | $14.39 | -98.43% |
| September, 2026 | $8.9701 | $8.1401 | $12.35 | -98.86% |
| October, 2026 | $6.4028 | $5.4828 | $8.8867 | -99.19% |
| November, 2026 | $5.9289 | $5.9289 | $7.7093 | -99.25% |
| December, 2026 | $5.3517 | $4.9966 | $6.652 | -99.32% |
Regencell Bioscience Holdings Ltd Stock (RGC) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Regencell Bioscience Holdings Ltd (RGC) is $8.8961, with a high forecast of $17.66 and a low forecast of $0.1344. This indicates an -98.87% decrease from the last price of $790.26.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $2.5677 | $2.5677 | $5.9881 | -99.68% |
| February, 2027 | $5.0839 | $2.3443 | $5.6838 | -99.36% |
| March, 2027 | $17.48 | $4.1169 | $10.27 | -97.79% |
| April, 2027 | $18.07 | $13.48 | $14.08 | -97.71% |
| May, 2027 | $5.6224 | $7.9624 | $17.66 | -99.29% |
| June, 2027 | $3.8701 | $7.2093 | $6.7332 | -99.51% |
| July, 2027 | $4.1352 | $1.3852 | $7.5021 | -99.48% |
| August, 2027 | $5.7475 | $0.1344 | $6.6675 | -99.27% |
| September, 2027 | $5.8728 | $2.5705 | $10.63 | -99.26% |
| October, 2027 | $6.3349 | $1.4989 | $8.0899 | -99.20% |
| November, 2027 | $4.1027 | $5.1927 | $2.4357 | -99.48% |
| December, 2027 | $2.8627 | $0.1373 | $4.3627 | -99.64% |
Regencell Bioscience Holdings Ltd Stock (RGC) Price Forecast for 2028
In 2028, Regencell Bioscience Holdings Ltd (RGC) is projected to reach an average price of $13.09, with a high projection of $23.58 and a low estimate of $2.5957. This indicates an -98.34% fall from the last price of $790.26.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $17.81 | $2.5957 | $23.58 | -97.75% |
| February, 2028 | $14.23 | $4.3311 | $18.14 | -98.20% |
| March, 2028 | $8.9425 | $6.1764 | $19.60 | -98.87% |
| April, 2028 | $8.1248 | $4.2117 | $10.73 | -98.97% |
| May, 2028 | $11.06 | $8.0241 | $13.02 | -98.60% |
| June, 2028 | $10.01 | $3.5524 | $11.93 | -98.73% |
| July, 2028 | $10.62 | $7.1055 | $15.17 | -98.66% |
| August, 2028 | $11.14 | $9.8319 | $13.62 | -98.59% |
| September, 2028 | $12.25 | $9.7861 | $16.11 | -98.45% |
| October, 2028 | $13.17 | $7.6345 | $16.10 | -98.33% |
| November, 2028 | $11.34 | $11.08 | $15.03 | -98.57% |
| December, 2028 | $13.47 | $11.01 | $17.78 | -98.30% |
Regencell Bioscience Holdings Ltd Stock (RGC) Price Forecast for 2029
The 2029 price forecast for Regencell Bioscience Holdings Ltd Stock (RGC) is $10.18 on average, with a high prediction of $18.84 and a low estimate of $1.5285. This represents an -98.71% decrease from the previous price of $790.26.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $11.93 | $9.6613 | $16.08 | -98.49% |
| February, 2029 | $12.83 | $9.5506 | $18.84 | -98.38% |
| March, 2029 | $9.512 | $9.512 | $18.60 | -98.80% |
| April, 2029 | $3.1443 | $2.4443 | $9.1781 | -99.60% |
| May, 2029 | $6.2296 | $2.0765 | $8.6773 | -99.21% |
| June, 2029 | $10.20 | $5.8027 | $10.54 | -98.71% |
| July, 2029 | $8.3741 | $7.2711 | $10.77 | -98.94% |
| August, 2029 | $4.3795 | $4.3795 | $9.2072 | -99.45% |
| September, 2029 | $4.5723 | $3.0356 | $5.3787 | -99.42% |
| October, 2029 | $3.93 | $3.504 | $5.5379 | -99.50% |
| November, 2029 | $2.1693 | $2.1693 | $4.9871 | -99.73% |
| December, 2029 | $2.5015 | $1.5285 | $4.5324 | -99.68% |
Regencell Bioscience Holdings Ltd Stock (RGC) Price Forecast for 2030
Regencell Bioscience Holdings Ltd Stock (RGC) is expected to reach an average price of $18.24 in 2030, with a high forecast of $34.44 and a low forecast of $2.0472. This signifies an -97.69% decrease from the last price of $790.26.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $5.1377 | $2.3747 | $7.9008 | -99.35% |
| February, 2030 | $32.41 | $30.73 | $27.75 | -95.90% |
| March, 2030 | $29.70 | $32.45 | $34.44 | -96.24% |
| April, 2030 | $23.34 | $23.44 | $23.96 | -97.05% |
| May, 2030 | $15.00 | $20.88 | $22.81 | -98.10% |
| June, 2030 | $15.55 | $14.00 | $15.54 | -98.03% |
| July, 2030 | $6.0496 | $10.94 | $9.5984 | -99.23% |
| August, 2030 | $11.16 | $7.8304 | $8.6516 | -98.59% |
| September, 2030 | $17.40 | $12.40 | $15.25 | -97.80% |
| October, 2030 | $14.66 | $17.16 | $15.95 | -98.15% |
| November, 2030 | $0.7668 | $8.0668 | $12.64 | -99.90% |
| December, 2030 | $1.7534 | $2.0472 | $11.23 | -99.78% |
3.31%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):